Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.15, $0.08 better than the analyst estimate of $0.07. Revenue for the quarter came in at $65.5 million versus the consensus estimate of $67.11 million.

EXPAREL net product revenues were $63.8 million in the first quarter of 2016, compared to $56.0 million in the first quarter of 2015.

Pacira Pharma reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins